Skip to main content
  • About ELGA
    • About ELGA
    • Ultrapure water
    • Purification Technologies
    • Impurities In Water
    • Guides & White Papers
    • Approved Partners
    • Sustainability
    • Reducing Clinical Risks
    • Careers
    • Events
    • HPLC in Pharma
    • HPLC Water Purity
  • Blog
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment and sustainability
    • Life in the lab
    • Purelab product design
    • Science of the future
    • Water Purity
    • Water in the lab
  • Contact
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 日本語
  • 中文
Home ELGA LabWater
  • Products
  • Applications
  • Case Studies
  • Support
  • Products
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA Full Product Range
  • Applications
  • Case Studies
    • Abbott Diagnostics chooses ELGA MEDICA systems in South Asia
    • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
    • Clean Water for a Clean Future
    • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
    • DASA: The biggest medical diagnostics company in Brazil
    • ELGA helps immuneserology labs maximize uptime
    • Importance of ultrapure Type 1+ water for the development of generic medicines
    • MEDICA® Pro selected for Siemens ADVIA® analyzers at City General Hospital
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
    • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
    • PURELAB® flex: an ideal training system for today's research method
    • Powering Cutting-Edge Gene Research
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • ELGA LabWater and Beckman Coulter Join Forces
    • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
    • Unlocking the secrets of the Antarctic with the aid of ultrapure water
    • Advancing Genetic Technologies
    • Cross Infection Control: Pure and Simple
    • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
  • Support
    • Support & Services
    • Laboratory Planning
    • Register a Product
    • Register Your Product (USA & Canada Only)
  • Products
    • PURELAB
      • PURELAB Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB Chorus 2+
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® flex 1 & 2
      • PURELAB® flex 3 & 4
    • CENTRA
      • CENTRA® 60/120
      • CENTRA® RDS
      • CENTRA® R200
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® EDI 15/30
      • MEDICA® Pro EDI 60/120
      • MEDICA® Pro-LPS
      • MEDICA® Pro-R and Pro-RE
      • MEDICA® R200
    • BIOPURE
      • BIOPURE 7/15
      • BIOPURE 60/120
      • BIOPURE 200/300/600
    • ELGA Full Product Range
      • PURELAB® Classic
  • Applications
  • Case Studies
    • Abbott Diagnostics chooses ELGA MEDICA systems in South Asia
    • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
    • Clean Water for a Clean Future
    • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
    • DASA: The biggest medical diagnostics company in Brazil
    • ELGA helps immuneserology labs maximize uptime
    • Importance of ultrapure Type 1+ water for the development of generic medicines
    • MEDICA® Pro selected for Siemens ADVIA® analyzers at City General Hospital
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
    • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
    • PURELAB® flex: an ideal training system for today's research method
    • Powering Cutting-Edge Gene Research
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • ELGA LabWater and Beckman Coulter Join Forces
    • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
    • Unlocking the secrets of the Antarctic with the aid of ultrapure water
    • Advancing Genetic Technologies
    • Cross Infection Control: Pure and Simple
    • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
  • Support
    • Support & Services
    • Laboratory Planning
    • Register a Product
    • Register Your Product (USA & Canada Only)
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 日本語
  • 中文
  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Impressum

Let's talk about lab water

  • Categories
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment & Sustainability
    • Future Science
    • Life in The Lab
    • PURELAB Product Design
    • Science of the Future
    • Water In The Lab
    • Water Purity
  • Authors
    • ELGA Editorial Team
    • Natasha Zarach
    • Dr Paul Whitehead
    • Dr Alison Halliday
    • John Walker
Clinical & Pharma
Science of the Future

A New Technique For Quantifying Bevacizumab In Eye Formulations

23 Feb 2020
- by Dr Alison Halliday

Child eye test

Bevacizumab is a cancer drug that is also used ‘off-label’ to treat eye diseases. Researchers develop a rapid, sensitive and cost-effective new method for its routine analysis in ocular formulations.

Bevacizumab (Avastin®) is a monoclonal antibody that is approved for treating several types of cancer. By targeting the activity of vascular endothelial growth factor-A (VEGF-A) and blocking the growth of tumour blood vessels, this effectively cuts off the supply of oxygen and nutrients that fuel the tumour.

But ophthalmologists also use bevacizumab to treat chronic eye diseases caused by abnormal blood vessel growth in the retina at the back of the eye. These include the ‘wet’ type of age-related macular degeneration (AMD), which is a leading cause of blindness in older people. By injecting the antibody directly into the patient’s eyes, the aim is to block the growth of blood vessels and slow down sight loss. 

Although bevacizumab is not formally approved as an eye treatment, many consider it as an equally effective, yet cheaper alternative to a similar antibody called ranibizumab (Lucentis®) – which also targets VEGF-A and has been approved for this purpose.

Challenges Around Drug Delivery and Quality Control

A patient will need repeated doses of bevacizumab around every four to six weeks to maintain the drug at therapeutic levels in their eyes. But these injections are invasive and bring risks of potential complications. So scientists are aiming to develop sustained release systems – such as eye implants – that can enable longer-lasting delivery.

Another challenge is that biotherapeutic antibodies are not very stable – for example, they can aggregate, unfold or degrade, which can impact on their effectiveness. And so it is important that processes are in place that can facilitate the quality control of bevacizumab in eye formulations.

A Faster, Simpler and Cheaper Method

In a new study, researchers develop a new analytical method for use in in vitro studies of new eye implant delivery systems and in the routine quantification of bevacizumab in ophthalmic formulations.1 The scientists used size-exclusion chromatography (SEC) coupled with fluorescence detection. This is a powerful tool used for the preparation of biotherapeutics and represents a feasible alternative for other assays currently available for quantifying bevacizumab, which are both costly and time-consuming.

The researchers optimised their unique new chromatographic technique and then validated it for bevacizumab analysis, demonstrating that it is accurate, rapid and sensitive. The researchers made up the stock and standard solutions required for these experiments using an ELGA PURELAB® Flex laboratory water purification system.

This is the first study that couples SEC with fluorescence detector for the assay of bevacizumab. The results demonstrate that this method is cost-effective and suitable for the routine analysis of bevacizumab in pharmaceutical dosage forms –  and for measuring its levels in in vitro release studies of drug-loaded eye implants.

Why choose ELGA LabWater?

ELGA LabWater has been a trusted name in pure and ultrapure water since 1937. Our dedication to ultrapure and pure water is a guarantee that we will continue to provide the best solutions with the best service.

Reference:

  1. Jirgees, F. et al. A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations. Journal of Pharmaceutical and Biomedical Analysis 2019; 174: 145-150.

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

 

Highlights

22 Feb 2021
Challenges in the Purification of Drinking Water Part 2
15 Feb 2021
Challenges in the Purification of Drinking Water Part 1
8 Feb 2021
Exploring the Ancient Hair Proteome
25 Jan 2021
Could Hemp Seeds Provide A Natural Sleep Aid?
18 Jan 2021
Forensic Toxicological Analysis Of Cannabinoids In Blood
14 Dec 2020
Developing Batteries Powered by Human Urine 
23 Nov 2020
Improving the Treatment of Diabetic Foot Infections
16 Nov 2020
Does The Type Of Wine Fermentation Vessel Matter?

Categories

  • Analytical Chemistry
  • Clinical & Pharma
  • Cool Science
  • Environment & Sustainability
  • Future Science
  • Life in The Lab
  • PURELAB Product Design
  • Science of the Future
  • Water In The Lab
  • Water Purity

Video

  • Enquiry
  • Get a Quote
  • Book a Demo
  • Find an Approved Partner

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Get a Quote

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Book a Demo

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater Head Quarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
T: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

The Ultrapure Water Specialists

  • Support & Services
  • Events

Case Studies

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Olsberg Vocational College

Resources

  • Learn About Ultrapure Water
  • Guides and White Papers
  • Purification Technologies
  • Applications
  • Impurities In Water

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Language
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Other Veolia Sites
    • Veolia
    • Veolia Fondation
    • Veolia Water Technologies

© VWS (UK) Ltd. trading as ELGA LabWater. 2021 - All rights reserved.
ELGA is the global laboratory water brand name of Veolia.

  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Impressum
Elga Veolia
TOP

© 2017 ELGA Veolia